Contrast maker Bracco moves into AI image reading with cleared aneurysm software
Bracco and Avicenna.AI announced 510(k) clearances for two brain aneurysm programs that read head CT angiography scans, the first products in Bracco's UPTUNITY AI line. Avicenna.AI will lead U.S. sales.

Bracco, a diagnostic imaging company whose products include contrast agents, now has software under its own brand for reading the scans those agents help produce. Bracco and French AI developer Avicenna.AI announced Nov. 13 that the Food and Drug Administration has cleared two programs that analyze head CT angiography images for brain aneurysms, sold together as UPTUNITY | Aneurysm.
The products are the first in UPTUNITY, a new Bracco portfolio of AI-enabled decision support tools. Avicenna.AI, based in La Ciotat, France, holds both clearances and will lead U.S. promotion and distribution, the companies said.
Why it matters: Bracco said the line expands its digital health strategy into interpretive AI, a step beyond contrast agents and its existing MRI enhancement software, AiMIFY. The arrangement pairs a contrast-agent supplier with a radiology AI developer, with the developer holding the FDA clearances and handling U.S. sales. Neither company disclosed pricing or financial terms of the partnership.
Two clearances, two jobs
FDA's database lists CINA-Aneurysm, K262062, as cleared Oct. 20 and CINA-Aneurysm+, K262147, as cleared Oct. 19, both traditional 510(k)s reviewed by the radiology panel. The companies market them as UPTUNITY | Aneurysm Detection and UPTUNITY | Aneurysm Management. Radiology accounted for 33 of the 293 clearances FDA issued in October, according to openFDA data.
CINA-Aneurysm is cleared as computer-assisted detection and diagnosis software, a concurrent reading aid that flags suspected saccular brain aneurysms larger than 3 millimeters and reports their location and size. FDA's clearance letter says the agency also cleared a predetermined change control plan for it, which lets the company make certain planned changes without a new 510(k). Its predicate, according to the 510(k) summary, is GE Medical Systems' Critical Care Suite with Pneumothorax Detection AI Algorithm.
CINA-Aneurysm+ measures known, untreated aneurysms and, when two exams from the same patient are available, compares them over time. Its indications state that a clinician must review and accept or reject the output and that it is not a diagnostic device.
"A small incidental aneurysm on a head CTA can easily be overlooked when the worklist keeps growing," Cosimo DePinto, executive vice president of marketing and commercial operations at Bracco Americas, said in the announcement.
What the filings report
Avicenna.AI's 510(k) summary for CINA-Aneurysm describes a retrospective study of 423 cases in which the software had a sensitivity of 94.4% and a specificity of 91.7% against a panel of three neuroradiologists. In a separate study of eight radiologists reading 230 cases with and without the software, the primary measure of reader accuracy rose from 0.9375 to 0.9497, a difference the summary says did not establish formal superiority. The summary reports that reader sensitivity rose to 96.2% from 92.2% and mean reading time fell by 9.9 seconds per case.
The partnership and what comes next
Bracco and Avicenna.AI announced their partnership in March 2026 to develop AI for contrast-enhanced CT. Bracco, founded in 1927, says it has more than 4,000 employees and annual revenue of about 2 billion euros. Avicenna.AI was founded in 2018 by Cyril Di Grandi and Dr. Peter Chang.
The companies plan to show the product at the Radiological Society of North America's annual meeting in Chicago, Nov. 29 to Dec. 3, as they prepare a U.S. commercial launch. They did not give a launch date.



